BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for ...
CEO Shankar Musunuri highlighted advancements in Ocugen’s modifier gene therapy platform, specifically targeting three biologics license application (BLA) filings over the next three years. OCU400, ...
Taysha Gene Therapies, Inc. announced key updates on its TSHA-102 program, an investigational gene therapy for Rett syndrome, at the upcoming 2025 International Rett Syndrome Foundation Scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback